AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, has acquired a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer, and the STYL’One Nano compaction simulator—thereby enhancing its early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
 
“Continued pressure on pharma to reduce costs and shorten timelines requires CDMOs to offer services that enable doing more with less, such as API sparing development techniques and tools to streamline tech transfer from bench to the manufacturing suite,” said Elizabeth Hickman, chief business officer of AustinPx.
 
“The introduction of these technologies underscores our commitment to innovation and our clients’ success,” said Justin Keen, Senior Vice President, Operations. “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
 
The expanded capabilities are now available for use.